Investigational Drug Information for Famitinib
✉ Email this page to a colleague
What is the drug development status for Famitinib?
Famitinib is an investigational drug.
There have been 59 clinical trials for Famitinib.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 20th 2023.
The most common disease conditions in clinical trials are Breast Neoplasms, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Sun Yat-sen University.
There are one hundred and twenty-four US patents protecting this investigational drug and two hundred and ninety-five international patents.
Summary for Famitinib
| US Patents | 124 |
| International Patents | 295 |
| US Patent Applications | 317 |
| WIPO Patent Applications | 105 |
| Japanese Patent Applications | 17 |
| Clinical Trial Progress | Phase 3 (2023-08-20) |
| Vendors | 21 |
Recent Clinical Trials for Famitinib
| Title | Sponsor | Phase |
|---|---|---|
| A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer | Qinglei Gao | PHASE2 |
| A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | PHASE2 |
| Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma. | Fudan University | PHASE2 |
Clinical Trial Summary for Famitinib
Top disease conditions for Famitinib
Top clinical trial sponsors for Famitinib
US Patents for Famitinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Famitinib | ⤷ Start Trial | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (Cambridge, MA) | ⤷ Start Trial |
| Famitinib | ⤷ Start Trial | Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis | Genentech, Inc. (South San Francisco, CA) | ⤷ Start Trial |
| Famitinib | ⤷ Start Trial | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Start Trial |
| Famitinib | ⤷ Start Trial | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | Array BioPharma Inc. (Boulder, CO) | ⤷ Start Trial |
| Famitinib | ⤷ Start Trial | Methods of treatment of malignancies | Celgene Corporation (Summit, NJ) Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Famitinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Famitinib | European Patent Office | EP3344624 | 2035-09-02 | ⤷ Start Trial |
| Famitinib | Hong Kong | HK1256997 | 2035-09-02 | ⤷ Start Trial |
| Famitinib | Japan | JP2018532706 | 2035-09-02 | ⤷ Start Trial |
| Famitinib | Japan | JP2019172690 | 2035-09-02 | ⤷ Start Trial |
| Famitinib | Japan | JP2021130712 | 2035-09-02 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
